Evidence map›Paper›PMID 29975287›Full record

Trial reportMenopause (New York, N.Y.)2019

Apolipoprotein E4 genotype in combination with poor metabolic profile is associated with reduced cognitive performance in healthy postmenopausal women: implications for late onset Alzheimer's disease.

Roksana Karim, Melissa Koc, Jamaica R Rettberg, Howard N Hodis, Victor W Henderson, Jan A St John, Hooman Allayee, Roberta D Brinton, Wendy J Mack

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Menopause (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Carotid intima media thickness and white matter hyperintensity volume among midlife women.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Precision hormone therapy: identification of positive responders.Climacteric : the journal of the International Menopause Society · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. APOE genotype affects metabolic and Alzheimer-related outcomes induced by Western diet in female EFAD mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  13. Review
  14. How would we combat menopause as an Alzheimer's risk factor?Expert review of neurotherapeutics · 2018
    Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Roksana KarimDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.
Melissa KocDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.
Jamaica R Rettberg23andMe, Mountain View, CA.
Howard N HodisDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.
Victor W HendersonDepartments of Health Research and Policy (Epidemiology), and Neurology and Neurosciences, Stanford University, Stanford, CA.
Jan A St JohnDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.
Hooman AllayeeDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.
Roberta D BrintonDepartment of Pharmacology and Pharmaceutical Science, School of Pharmacy, University of Southern California, Los Angeles, CA.
Wendy J MackDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.
University of Southern California · US23andMe (United States) · USStanford Health Care · USUniversity of Arizona · US

Funding

Timing of Menopausal Hormone Therapy across Perimenopause to Menopause Transition: Neuroimmune System in BrainP01AG026572 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROBERTA EILEEN BRINTON · 2006 to 2026
$53.7M
Biologic Response of Menopausal Women to 17B-EstradiolR01AG024154 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HODIS, HOWARD NEIL · 2004 to 2012
$13.8M
NIA NIH HHS P01 AG026572NIA NIH HHS R01 AG024154
6 · The paper itself

Abstract

objectiveWe hypothesized the association of metabolic profile on cognition in postmenopausal women will be greater among ApoE4 carriers compared with noncarriers.

methodsMetabolic biomarkers and measures of global cognition, executive functions, and verbal memory, collected among postmenopausal females, were used in this analysis. Clustering analyses of metabolic biomarkers revealed three phenotypes: healthy, predominantly hypertensive, and poor metabolic with (borderline normal laboratory values). General linear models tested whether an association of metabolic cluster with cognition differed by ApoE4 genotype.

resultsIn the total sample of 497 women, verbal memory was lower in the poor metabolic cluster (P = 0.04). Among ApoE4+ women, performance in all cognitive domains was lowest in the poor metabolic cluster. Differences in executive functions among metabolic clusters were detected only in ApoE4+ women (P value for interaction = 0.003).

conclusionsIn a general population of postmenopausal women, association between poor metabolic profile with reduction in cognitive performance is more apparent in women who carry an ApoE4 allele. These data indicate a window of opportunity for interventions to reverse the trajectory of the preclinical phase of Alzheimer's disease.

Indexed as

Genetic Predisposition to DiseaseAgedAllelesAlzheimer DiseaseApolipoprotein E4BiomarkersCognitionDouble-Blind MethodExecutive FunctionFemaleHeterozygoteHumansMemoryMetabolomeMiddle AgedNeuropsychological TestsApolipoprotein E4Biomarkers

Identifiers

PMID29975287
PMCPMC7508039
OpenAlexW2810358023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.